Procalcitonin and sepsis: Recent data on diagnostic utility prognostic potential and therapeutic implications in critically ill patients

Minerva Anestesiologica

Volumn 78, Issue 7, 2012, Pages 823-835

  Kopterides, P ^a   Tsangaris, I ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Biological markers; Critical illness; Sepsis

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROADRENOMEDULLIN; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA;

ALGORITHM; APACHE; AREA UNDER THE CURVE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CRITICALLY ILL PATIENT; DISEASE SEVERITY; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; IMMUNE DEFICIENCY; INFLUENZA A (H1N1); INTENSIVE CARE UNIT; MORTALITY; PATIENT MONITORING; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEPSIS; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CALCITONIN; CRITICAL CARE; CRITICAL ILLNESS; HUMANS; INTENSIVE CARE; PROGNOSIS; PROTEIN PRECURSORS; SEPSIS; TREATMENT OUTCOME;

EID: 84864858142     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD et al.; EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-9.
2. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007;35:1244-50.
3. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
4. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
5. Harris RL, Musher DM, Bloom K, Gathe J, Rice L, Sugarman B et al. Manifestations of sepsis. Arch Intern Med 1987;147:1895-906.
6. Livermore DM. Minimising antibiotic resistance. Lancet Infect Dis 2005;5:450-9.
7. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96.
8. Pierrakos C, Vincent JL. Sepsis biomarkers: A review. Crit Care 2010;14:R15.
9. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515-8.
10. Becker KL, Nylén ES, White JC, Müller B, Snider RH Jr. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004;89:1512-25.
11. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206-17.
12. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and metaanalysis. Crit Care Med 2006;34:1996-2003.
13. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007;7:210-7.
14. Dahaba AA, Metzler H. Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator? Minerva Anestesiol 2009;75:447-52.
15. Müller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001;86:396-404.
16. Linscheid P, Seboek D, Nylén ES, Langer I, Schlatter M, Becker KL et al. In vitro and in vivo calcitonin-1 gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology 2003;144:5578-84.
17. Becker K, Snider R, Nylen E. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol 2010;159:253-64.
18. Reinhart K, Meisner M. Biomarkers in the critically ill patient: procalcitonin. Crit Care Clin 2011;27:253-63.
19. Zazula R, Prucha M, Tyll T, Kieslichova E. Induction of procalcitonin in liver transplant patients treated with antithymocyte globulin. Crit Care 2007;11:R131.
20. Brodska H, Drabek T, Malickova K, Kazda A, Vitek A, Zima T et al. Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a prospective study. Crit Care 2009;13:R37.
21. Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann Emerg Med 2007 2007;50:34-41.
22. O'Grady NP, Barie PS, Bartlett JG, Bleck T, Carroll K, Kalil AC et al. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med 2008;36:1330-49.
23. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
24. Charles PE, Ladoire S, Snauwaert A, Prin S, Aho S, Péchinot A et al. Impact of previous sepsis on the accuracy of procalcitonin for the early diagnosis of blood stream infection in critically ill patients. BMC Infect Dis 2008;8:163.
25. Schneider CP, Yilmaz Y, Kleespies A, Jauch KW, Hartl WH. Accuracy of procalcitonin for outcome prediction in unselected postoperative critically ill patients. Shock 2009;31:568-73.
26. Maier M, Wutzler S, Lehnert M, Szermutzky M, Wyen H, Bingold T et al. Serum procalcitonin levels in patients with multiple injuries including visceral trauma. J Trauma 2009;66:243-9.
27. Mofidi R, Suttie SA, Patil PV, Ogston S, Parks RW. The value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis: systematic review. Surgery 2009;146:72-81.
28. Mann EA, Wood GL, Wade CE. Use of procalcitonin for the detection of sepsis in the critically ill burn patient: a systematic review of the literature. Burns 2011;37:549-58.
29. Spahr L, Morard I, Hadengue A, Vadas L, Pugin J. Procalcitonin is not an accurate marker of spontaneous bacterial peritonitis in patients with cirrhosis. Hepatogastroenterology 2001;48:502-5.
30. Kafkas N, Venetsanou K, Patsilinakos S, Voudris V, Antonatos D, Kelesidis K et al. Procalcitonin in acute myocardial infarction. Acute Card Care 2008;10:30-6.
31. Keze J, Hendrix MG, van den Bergh FA, Brouwer RM, Zijlstra JG. In critically ill patients the procalcitonin level can be misleading. Crit Care 2011;15:422.
32. Meynaar IA, Droog W, Batstra M, Vreede R, Herbrink P. In critically ill patients, serum procalcitonin is more useful in differentiating between sepsis and SIRS than CRP, Il-6, or LBP. Crit Care Res Pract 2011;2011:594645.
33. Charles PE, Kus E, Aho S, Prin S, Doise JM, Olsson NO et al. Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary report. BMC Infect Dis. 2009;9:49.
34. Tsangaris I, Plachouras D, Kavatha D, Gourgoulis GM, Tsantes A, Kopterides P et al. Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infect Dis 2009;9:213.
35. Nelson JE, Cox CE, Hope AA, Carson SS. Chronic critical illness. Am J Respir Crit Care Med 2010;182:446-54.
36. Iapichino G, Marzorati S, Umbrello M, Baccalini R, Barassi A, Cainarca M et al. Daily monitoring of biomarkers of sepsis in complicated long-term ICU-patients: can it support treatment decisions? Minerva Anestesiol 2010;76:814-23.
37. Piacentini E, Sánchez B, Arauzo V, Calbo E, Cuchi E, Nava JM. Procalcitonin levels are lower in intensive care unit patients with H1N1 influenza A virus pneumonia than in those with community-acquired bacterial pneumonia. A pilot study. J Crit Care 2011;26:201-5.
38. Hammond NE, Corley A, Fraser JF. The utility of procalcitonin in diagnosis of H1N1 influenza in intensive care patients. Anaesth Intensive Care 2011;39:238-41.
39. Cuquemelle E, Soulis F, Villers D, Roche-Campo F, Ara Somohano C, Fartoukh M et al. Can procalcitonin help identify associated bacterial infection in patients with severe influenza pneumonia? A multicentre study. Intensive Care Med 2011;37:796-800
40. Ingram PR, Inglis T, Moxon D, Speers D. Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection. Intensive Care Med 2010;36:528-32.
41. Mikuła T, Cianciara J, Wiercińska-Drapało A. Is there any influence of immune deficit on procalcitonin results? Hum Immunol 2011;72:1194-7.
42. Bele N, Darmon M, Coquet I, Feugeas JP, Legriel S, Adaoui N et al. Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients. BMC Infect Dis 2011;11:224.
43. Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P, Galani L, Anagnostopoulos N, Grecka P et al. Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect 2004;10:628-33.
44. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 2008;36:396-407.
45. Robinson JO, Lamoth F, Bally F, Knaup M, Calandra T, Marchetti O. Monitoring procalcitonin in febrile neutropenia: What is its utility for initial diagnosis of infection and reassessment in persistent fever? PLoS One 2011;6:e18886.
46. Lin CH, Yao M, Hsu SC, Ho CC, Lin MT, Lin CA et al. Soluble triggering receptor expressed on myeloid cells-1 as an infection marker for patients with neutropenic fever. Crit Care Med 2011;39:993-9.
47. Gac AC, Parienti JJ, Chantepie S, Fradin S, Le Coutour X, Leclercq R et al. Dynamics of procalcitonin and bacteremia in neutropenic adults with acute myeloid leukemia. Leuk Res 2011;35:1294-6.
48. Koivula I, Hamalainen S, Jantunen E, Pulkki K, Kuittinen T, Nousiainen T et al. Elevated procalcitonin predicts gramnegative sepsis in hematological patients with febrile neutropenia. Scand J Infect Dis 2011;43:471-8.
49. Cornillon J, Bouteloup M, Lambert C. Evaluation of procalcitonin and CRP as sepsis markers in 74 consecutive patients admitted with prolonged febrile neutropenia. J Infect 2011;63:93-5.
50. Meisner M, Adina H, Schmidt J. Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. Crit Care 2006;10:R1.
51. Castelli GP, Pognani C, Cita M, Paladini R. Procalcitonin as a prognostic and diagnostic tool for septic complications after major trauma. Crit Care Med 2009;37:1845-9.
52. Billeter A, Turina M, Seifert B, Mica L, Stocker R, Keel M. Early serum procalcitonin, interleukin-6, and 24-hour lactate clearance: useful indicators of septic infections in severely traumatized patients. World J Surg 2009;33:558-66.
53. Castelli GP, Pognani C, Cita M, Stuani A, Sgarbi L, Paladini R. Procalcitonin, C-reactive protein, white blood cells and SOFA score in ICU: diagnosis and monitoring of sepsis. Minerva Anestesiol 2006;72:69-80.
54. Lavrentieva A, Papadopoulou S, Kioumis J, Kaimakamis E, Bitzani M. PCT as a diagnostic and prognostic tool in burn patients. Whether time course has a role in monitoring sepsis treatment. Burns 2012;38:356-63.
55. Clec'h C, Fosse JP, Karoubi P, Vincent F, Chouahi I, Hamza L et al. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med 2006;34:102-7.
56. Novotny AR, Emmanuel K, Hueser N, Knebel C, Kriner M, Ulm K et al. Procalcitonin ratio indicates successful surgical treatment of abdominal sepsis. Surgery 2009;145:20-6.
57. Hunziker S, Hügle T, Schuchardt K, Groeschl I, Schuetz P, Mueller B, et al. The value of serum procalcitonin level for differentiation of infectious from noninfectious causes of fever after orthopaedic surgery. J Bone Joint Surg Am 2010;92:138-48.
58. Giamarellos-Bourboulis EJ, Mega A, Grecka P, Scarpa N, Koratzanis G, Thomopoulos G et al. Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient? Intensive Care Med 2002;28:1351-6.
59. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006;34:2596-2602.
60. Suberviola B, Castellanos-Ortega A, González-Castro A, García-Astudillo LA, Fernández-Miret B. Prognostic value of procalcitonin, C-reactive protein and leukocytes in septic shock. Med Intensiva 2011;[Epub ahead of print].
61. Giamarellos-Bourboulis EJ, Tsangaris I, Kanni T, Mouktaroudi M, Pantelidou I, Adamis G et al; Hellenic Sepsis Study Group. Procalcitonin as an early indicator of outcome in sepsis: a prospective observational study. J Hosp Infect 2011;77:58-63.
62. Tasdelen Fisgin N, Aliyazicioglu Y, Tanyel E, Coban AY, Ulger F, Zivalioglu M et al. The value of neopterin and procalcitonin in patients with sepsis. South Med J 2010;103:216-9.
63. Rammaert B, Verdier N, Cavestri B, Nseir S. Procalcitonin as a prognostic factor in severe acute exacerbation of chronic obstructive pulmonary disease. Respirology 2009;14:969-74.
64. Kasamatsu Y, Yamaguchi T, Kawaguchi T, Tanaka N, Oka H, Nakamura T et al. Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale, for predicting mortality among adults hospitalized with community-acquired pneumonia. Respirology 2012;17:330-6.
65. Haeuptle J, Zaborsky R, Fiumefreddo R, Trampuz A, Steffen I, Frei R et al. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis 2009;28:55-60.
66. Bloos F, Marshall JC, Dellinger RP, Vincent JL, Gutierrez G, Rivers E et al. Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study. Crit Care 2011;15:R88.
67. Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T; German Competence Network for the Study of Community Acquired Pneumonia (CAPNETZ) Study Group. Cardiovascular and inflammatory biomarkers to predict shortand long-term survival in communityacquired pneumonia: Results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010;182:1426-34.
68. Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B; Procalcitonin-guided antibiotic therapy and hospitalisation in patients with lower respiratory tract infections (ProHOSP) Study Group. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 2011;37:384-92.
69. Boeck L, Eggimann P, Smyrnios N, Pargger H, Thakkar N, Siegemund M et al. Midregional pro-atrial natriuretic peptide and procalcitonin improve survival prediction in VAP. Eur Respir J 2011;37:595-603.
70. Horie M, Ugajin M, Suzuki M, Noguchi S, Tanaka W, Yoshihara H et al. Diagnostic and prognostic value of procalcitonin in community-acquired pneumonia. Am J Med Sci 2012;343:30-5.
71. Haasper C, Kalmbach M, Dikos GD, Meller R, Müller C, Krettek C et al. Prognostic value of procalcitonin (PCT) and/or interleukin-6 (IL-6) plasma levels after multiple trauma for the development of multi organ dysfunction syndrome (MODS) or sepsis. Technol Health Care 2010;18:89-100.
72. van den Broek MA, Olde Damink SW, Winkens B, Broelsch CE, Malagó M, Paul A et al. Procalcitonin as a prognostic marker for infectious complications in liver transplant recipients in an intensive care unit. Liver Transpl 2010;16:402-10.
73. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I et al; ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the Pro-HOSP randomized controlled trial. JAMA 2009;302:1059-66.
74. Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93.
75. Burkhardt O, Ewig S, Haagen U, Giersdorf S, Hartmann O, Wegscheider K et al. Procalcitonin guidance and reductions of antibiotic use in acute respiratory tract infection. Eur Respir J 2010;36:601-7.
76. Svoboda P, Kantorová I, Scheer P, Radvanova J, Radvan M. Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery? Hepatogastroenterology 2007;54:359-63.
77. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008;177:498-505.
78. Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 2009;394:221-6.
79. Hochreiter M, Köhler T, Schweiger AM, Keck FS, Bein B, von Spiegel T et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009;13:R83.
80. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009;34:1364-75.
81. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C et al.; PRORATA trial group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463-74.
82. Kopterides P, Siempos II, Tsangaris I, Tsantes A, Armaganidis A. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med 2010;38:2229-41.
83. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011;39:1792-9.
84. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis 2011;53:379-87.
85. Li H, Luo YF, Blackwell TS, Xie CM. Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections. Antimicrob Agents Chemother 2011;55:5900-6.
86. Tokman S, Schuetz P, Bent S. Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations. Expert Rev Anti Infect Ther 2011;9:727-35.
87. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011;171:1322-31.
88. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004;125:1791-9.
89. Cunha BA. Procalcitonin vs clinical and chest film findings to diagnose community-acquired pneumonia in patients with acute asthma or acute exacerbations of chronic bronchitis. Chest 2011;140:1667-8.
90. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH et al; Procalcitonin And Survival Study (PASS) Group. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial. Crit Care Med 2011;39:2048-58.
91. Placebo controlled trial of sodium selenite and procalcitonin guided antimicrobial therapy in severe sepsis (SISPCT). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00832039. Accessed: November 28, 2011.
92. Safety and efficacy of procalcitonin guided antibiotic therapy in adult intensive care units (ICU's) (SAPS). [cited 2012 May 23]. Available at: http://clinicaltrials.gov/ct2/show/NCT01139489.